EP1883419A4 - Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use - Google Patents

Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use

Info

Publication number
EP1883419A4
EP1883419A4 EP06759154A EP06759154A EP1883419A4 EP 1883419 A4 EP1883419 A4 EP 1883419A4 EP 06759154 A EP06759154 A EP 06759154A EP 06759154 A EP06759154 A EP 06759154A EP 1883419 A4 EP1883419 A4 EP 1883419A4
Authority
EP
European Patent Office
Prior art keywords
glp
glucagon
peptide
receptor agonists
pharmacological methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06759154A
Other languages
German (de)
French (fr)
Other versions
EP1883419A2 (en
Inventor
James Whelan
Kevin Lumb
Kevin Clairmont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of EP1883419A2 publication Critical patent/EP1883419A2/en
Publication of EP1883419A4 publication Critical patent/EP1883419A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP06759154A 2005-05-06 2006-05-05 Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use Withdrawn EP1883419A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67872305P 2005-05-06 2005-05-06
PCT/US2006/017411 WO2006121860A2 (en) 2005-05-06 2006-05-05 Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use

Publications (2)

Publication Number Publication Date
EP1883419A2 EP1883419A2 (en) 2008-02-06
EP1883419A4 true EP1883419A4 (en) 2010-08-04

Family

ID=37397130

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06759154A Withdrawn EP1883419A4 (en) 2005-05-06 2006-05-05 Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use

Country Status (4)

Country Link
EP (1) EP1883419A4 (en)
JP (1) JP2008539735A (en)
CA (1) CA2607566A1 (en)
WO (1) WO2006121860A2 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
EP2650006A1 (en) * 2007-09-07 2013-10-16 Ipsen Pharma S.A.S. Analogues of exendin-4 and exendin-3
DE102007054497B3 (en) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh New crystalline hydrate form of dodecanedioic acid 4-((2S,3R)-3-((S)-3-(4-fluoro-phenyl)-3-hydroxy-propyl)-2-(4-methoxy-phenyl)-4-oxo-azetidin-1-yl)-benzylamide ((2S,3R,4R,5R)-pentahydroxy-hexyl)-amide useful e.g. to treat hyperlipidemia
CA2707448C (en) * 2007-12-11 2014-10-14 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
HUE026255T2 (en) 2009-07-13 2016-06-28 Zealand Pharma As Acylated glucagon analogues
CN102482312A (en) 2009-08-26 2012-05-30 赛诺菲 Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
TW201124391A (en) 2009-10-20 2011-07-16 Lundbeck & Co As H 2-substituted-ethynylthiazole derivatives and uses of same
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
AR080592A1 (en) * 2010-03-26 2012-04-18 Lilly Co Eli PEPTIDE WITH ACTIVITY FOR GIP-R AND GLP-1-R, FAMILY FORMULATION THAT UNDERSTANDS IT, ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF MELLITUS DIABETES AND TO INDICATE WEIGHT LOSS
DE102010015123A1 (en) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (en) 2011-03-08 2014-12-17 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683699B1 (en) 2011-03-08 2015-06-24 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US20120282255A1 (en) * 2011-04-07 2012-11-08 Greg Plucinski Methods and compositions for the treatment of alcoholism and alcohol dependence
JP6148228B2 (en) 2011-05-18 2017-06-14 ユーメデリス ファーマシューティカルズ，インク． Improved peptide formulation
RU2602801C2 (en) * 2011-05-18 2016-11-20 МЕДЕРИС ДАЙАБИТИЗ, ЭлЭлСи Peptide drugs with high effectiveness against insulin resistance
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
IN2014MN02304A (en) 2012-05-03 2015-08-07 Zealand Pharma As
FR2991055B1 (en) 2012-05-22 2014-06-13 C2 Diagnostics FLUIDIC CONNECTION DEVICE FOR BIOLOGICAL ANALYSIS APPARATUS, FLUIDIC COMPONENT ADAPTED AND BIOLOGICAL ANALYSIS APPARATUS THUS EQUIPPED THEREFOR;
CN104662038B (en) 2012-07-23 2018-11-06 西兰制药公司 Glucagon analogue
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analogues
AU2013329077A1 (en) * 2012-10-11 2015-04-23 Tufts University Compositions and methods for sustained delivery of glucagon-like peptide (GLP-1) receptor agonist therapeutics
US11065304B2 (en) 2012-11-20 2021-07-20 Mederis Diabetes, Llc Peptide pharmaceuticals for insulin resistance
EP4047023A1 (en) 2012-11-20 2022-08-24 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
EP3057984B1 (en) 2013-10-17 2018-07-11 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
TR201902516T4 (en) 2013-11-06 2019-03-21 Zealand Pharma As Glucagon-glp-1-envy triple agonist compounds.
CN105849122B (en) * 2013-11-06 2021-04-30 西兰制药公司 GIP-GLP-1 dual agonist compounds and methods
MX371033B (en) * 2014-05-28 2020-01-13 Mederis Diabetes Llc Improved peptide pharmaceuticals for insulin resistance.
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
ES2763329T3 (en) 2015-04-16 2020-05-28 Zealand Pharma As Acylated glucagon analog
KR20200106173A (en) 2018-01-03 2020-09-11 메더리스 다이어비티즈, 엘엘씨 Improved peptide drugs for the treatment of NASH and other diseases
EA202092269A1 (en) * 2018-03-23 2020-12-14 Кармот Терапьютикс, Инк. G-PROTEIN-COUPLED RECEPTOR MODULATORS
HUE060135T2 (en) 2018-04-05 2023-02-28 Sun Pharmaceutical Ind Ltd Novel glp-1 analogues
CN108676084B (en) * 2018-05-31 2021-12-03 长春百克生物科技股份公司 Exenatide modifier and application thereof
CN109021093B (en) * 2018-08-29 2021-09-07 上海生物制品研究所有限责任公司 Polyethylene glycol modified GLP-1 derivatives and medicinal salts thereof
CN111410687B (en) * 2020-02-21 2023-06-27 成都奥达生物科技有限公司 Long-acting GLP-1 compound
CN113461785B (en) * 2021-04-13 2022-10-14 湖南中晟全肽生化有限公司 GLP-1 receptor agonists and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043707A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO2000066629A1 (en) * 1999-04-30 2000-11-09 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
WO2004022004A2 (en) * 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
WO2004093823A2 (en) * 2003-03-19 2004-11-04 Eli Lilly And Company Polyethelene glycol link glp-1 compounds
US6864069B2 (en) * 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US7067488B2 (en) * 2002-09-25 2006-06-27 Theratechnologies Inc. Modified GLP-1 peptides with increased biological potency

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043707A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO2000066629A1 (en) * 1999-04-30 2000-11-09 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6864069B2 (en) * 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
WO2004022004A2 (en) * 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
WO2004093823A2 (en) * 2003-03-19 2004-11-04 Eli Lilly And Company Polyethelene glycol link glp-1 compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROBERTS M J ET AL: "Chemistry for peptide and protein PEGylation", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL LNKD- DOI:10.1016/S0169-409X(02)00022-4, vol. 54, no. 4, 17 June 2002 (2002-06-17), pages 459 - 476, XP002293146, ISSN: 0169-409X *
VERONESE F M: "Peptide and protein PEGylation - a review of problems and solutions", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB LNKD- DOI:10.1016/S0142-9612(00)00193-9, vol. 22, no. 5, 1 March 2001 (2001-03-01), pages 405 - 417, XP004227886, ISSN: 0142-9612 *

Also Published As

Publication number Publication date
JP2008539735A (en) 2008-11-20
WO2006121860A2 (en) 2006-11-16
EP1883419A2 (en) 2008-02-06
WO2006121860A3 (en) 2007-04-12
CA2607566A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
EP1883419A4 (en) Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
AU2003273300A8 (en) Modified glp-1 receptor agonists and their pharmacological methods of use
HK1073117A1 (en) Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
HK1206241A1 (en) Glucagon-like peptide 1 (glp-1) pharmaceutical formulations 1(glp-1)
IL176223A0 (en) The glucagon-like peptide-1 receptor agonists, the preparation and the use of the same
IL177066A0 (en) Combined use of a glp-1 agonist and gastrin compounds
AU2003239478A8 (en) Modified glucagon-like peptide-1 analogs
WO2006097536A3 (en) Dimeric peptide agonists of the glp-1 receptor
IL189670A0 (en) Trail receptor 2 polypeptides and antibodies
EP1585959A4 (en) Extended glucagon-like peptide-1 analogs
HK1112006A1 (en) Antibodies against il-13 receptor alpha 1 and uses thereof
ZA200705674B (en) Peptides with neuropeptide-2 receptor (Y2R) agonist activity
AU5716901A (en) G protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
EP1583503A4 (en) Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
IL178254A0 (en) Receptor coupling agents and therapeutic uses thereof
ZA200703279B (en) Electrochemical dissolution of conductive composites
ZA200710699B (en) Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor
IL178690A0 (en) Peptidic vasopressin receptor agonists
EP1709071A4 (en) Glucagon-like peptide-1 analogs with long duration of action
ZA200802575B (en) Trail receptor 2 polypeptides and antibodies
EP1713493A4 (en) Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use
EP1896048A4 (en) Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use
PL370221A1 (en) 2-oxazolamines and their use as 5-ht2b receptor antagonists
EP1970062A4 (en) Novel cxcr4 antagonist and use thereof
AU2003276106A8 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071206

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20100701

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110202